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INTRODUCTION
Autologous stem cell transplantation (ASCT) has become
accepted as the treatment of choice for non-Hodgkin’s lym-
phoma (NHL) patients with relapsed chemosensitive dis-
ease, and the number of patients undergoing this approach
for NHL and for other chemosensitive tumors has increased
substantially over the past decade. Treatment-related mor-
tality is generally lower using this approach, and late com-
plications are evolving as signiﬁcant causes of morbidity and
mortality. A major complication of this approach is the
development of therapy-related myelodysplastic syndromes
and secondary acute myelogenous leukemia (t-MDS/AML).
The actuarial risk of developing t-MDS/AML after ASCT
for lymphoma is substantial. As shown in Table 1, the actu-
arial risk varies between centers, ranging from 3% to as high
as 24% of patients [1-9].
MDS AS A COMPLICATION OF ASCT FOR NHL
At Dana-Farber Cancer Institute (DFCI), we have
recently reviewed the incidence of the development of MDS
as a complication after ASCT for lymphoma. The outcomes
for 552 patients who had undergone ASCT for NHL
between 1982 and 1997 were reviewed [7]. Eligibility crite-
ria included patients with B-cell NHL expressing CD20,
aged up to 65 years. At DFCI, only patients with chemosen-
sitive disease were eligible for this approach; chemosensitiv-
ity was assessed by achievement of a minimal disease state
Evaluation of the Risk of Therapy-Related MDS/AML
After Autologous Stem Cell Transplantation
D. Gary Gilliland,1,2 John G. Gribben1,3
1Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School; 2Howard Hughes Medical 
Institute; 3Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Correspondence and reprint requests: D. Gary Gilliland, PhD, MD, Howard Hughes Medical Institute, 
Harvard Institutes of Medicine, 4 Blackfan Cir, Rm 418, Boston, MA, 02115; or John G. Gribben, MD, DSc, 
Dana-Farber Cancer Institute, 44 Binney St, Rm D520, Boston, MA 02115 (e-mail: john_gribben@dfci.harvard.edu).
Received September 25, 2001; accepted October 31, 2001
ABSTRACT
A major complication of autologous stem cell transplantation (ASCT) is the development of therapy-related
myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). This complication likely results from
previous exposure of the autologous stem cells to chemotherapy as well as to the high doses of chemotherapy and
radiation therapy that are used as part of the conditioning regimen. A number of centers are reporting that, second
to disease relapse, therapy-related MDS and AML are among the major causes of morbidity and mortality after
ASCT. There is abundant evidence that therapy-related MDS and AML are clonal hemopathies that are the conse-
quence of an acquired somatic mutation that confers a proliferative and/or survival advantage to hematopoietic pro-
genitors. However, no single mutation or gene rearrangement is sufficient for the development of therapy-related
AML, and the identification of a single gene rearrangement or point mutation may not necessarily be predictive of
the development of therapy-related AML in the post-ASCT setting, a caveat that must be kept in mind when risk is
assessed. There are at least 5 methods for assessing risk based on the presence of clonal abnormalities in hemato-
poietic cells, including standard cytogenetics, interphase fluorescence in situ hybridization, analysis for loss of het-
erozygosity, polymerase chain reaction for point mutations, and X-inactivation–based clonality assays. Each of these
approaches has strengths and weaknesses that are discussed here in detail. 
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after induction or salvage chemotherapy, with no nodal
masses greater than 2 cm and bone marrow involvement at
less than 10% of the intertrabecular space [10-12]. Those
patients who had residual masses greater than 2 cm could be
treated by localized radiation therapy to that site before pro-
ceeding to ASCT. All patients treated in this time period
underwent bone marrow harvest that was purged using a
cocktail of anti–B-cell monoclonal antibodies and comple-
ment. All patients received cyclophosphamide and total
body irradiation (TBI). Until 1994, all patients received TBI
at a dose of 1200 cGy in 6 fractions and, after 1994, received
1400 cGy in 7 fractions. One hundred twenty-six patients in
ﬁrst complete or partial remission received ASCT as consol-
idation therapy, and all other patients, the majority of whom
had follicular lymphoma, were treated after initial relapse
[13]. Patient characteristics are shown in Table 2. Forty-six
percent of patients remain alive and disease free, 16% are
alive after relapse, and 38% of patients have died of trans-
plantation complications or of progressive disease after
relapse. Treatment-related deaths occurring within 100 days
after ASCT were uncommon and occurred in 8 cases
(1.4%), with diffuse alveolar hemorrhage syndrome being
the most common cause of death in the early post–bone
marrow transplantation period. The causes of death occur-
ring after ASCT in these patients are shown in Figure 1.
Development of secondary MDS or acute leukemia has
emerged as the second most common cause of death in
these patients, with relapse of disease being the most com-
mon cause. On review of these cases, it became clear that
strict criteria were required to make the diagnosis of sec-
ondary MDS. A number of patients have relative pancytope-
nia post-ASCT, and many patients have dysplastic features
and cytogenetic abnormalities, but the majority of these
patients do not have secondary MDS.
A number of studies have examined the link between
cytogenetic abnormalities and development of t-MDS/AML.
In a study from City of Hope of 10 patients with clonal
cytogenetic abnormalities after ASCT, although 5 patients
developed t-MDS/AML, the other 5 remain alive with no
evidence of development of t-MDS on long-term follow-up
[4]. At DFCI, we have found that cytogenetic abnormalities
are a common occurrence in patients after ASCT, but that
less than 30% of these patients develop t-MDS. The clinical
signiﬁcance of such abnormalities remains unclear. There-
fore, the presence of clonal cytogenetic abnormalities alone
is not a clinically useful way to assess patients with t-MDS.
The criteria used to deﬁne t-MDS in the DFCI series are
shown in Figure 2. Based on these criteria, some patients iden-
tiﬁed in the original report from this center [14] as having
developed t-MDS have now been excluded. Of note, the
patients excluded using these criteria have not progressed to
t-MDS or AML. Based on these criteria, 44 patients at this
center (29 male and 15 female) have developed t-MDS/AML
post-ASCT for lymphoma. Twenty-ﬁve cases of t-MDS/AML
have occurred in patients with low-grade histology, and 19 cases
have occurred in patients with aggressive lymphoma (includ-
ing mantle-cell lymphoma [MCL]). The median age of these
patients was 46 years. Thirty-two patients received ASCT
as consolidation therapy after relapse, and 12 patients were
treated after initial induction therapy. We have observed no
difference in the actuarial risk of development of t-MDS/AML
in those patients treated after relapse compared to those
patients treated in ﬁrst remission. The interval from ASCT
to development of t-MDS was 47 months, with a range of
12 to 129 months post-ASCT. Of note, 13 patients were
diagnosed with t-MDS after having also relapsed with their
original disease. The actuarial risk of development of t-MDS
in these patients is shown in Figure 3. The prognosis of these
patients remains dismal and, as shown in Figure 4, these
patients have a median survival after diagnosis of less than
1 year [7]. Very similar data have been reported from other
centers. At St Bartholomew’s Hospital, 27 of 230 patients
developed t-MDS/AML at a median of 50 months (range,
11-104 months) post-ASCT [15]. An unusual feature in this
report was the ﬁnding that prior therapy with ﬂudarabine, an
Table 1. Actuarial Risk of t-MDS/AML After ASCT*
Institution Year Actuarial Risk
Minnesota 1996 13% at 6 y 
City of Hope 1998 9% at 9 y
Nebraska 1994 4% at 5 y
Dana-Faber 1999 20% at 10 y
Copenhagen 1997 24% at 43 mo
French Cooperative 1998 4% at 5 y
British Cooperative 1999 3% at 5 y
EMBT Cooperative 1999 5% at 5 y
*Adapted from Pederson-Bjergaard et al. Blood. 2000;95:3273-3279.
Table 2. Patient Characteristics






Aggressive (including MCL) 44%
Median age (range), y 44 (19-66)
Time of transplantation was first CR 23%
Figure 1. Causes of death after ASCT of 209 patients with NHL. Sec-
ond to relapse of disease, t-MDS/AML has emerged as the major cause
of death.
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agent that was rarely used in the patients undergoing ASCT
at Dana-Farber, was a signiﬁcant factor for the development
of t-MDS. The actuarial risk of development and the median
survival after diagnosis in this series was very similar to that
observed at our own center.
RISK FACTORS FOR T-MDS/AML AFTER ASCT:
PRETRANSPLANTATION THERAPY, STEM CELL
MOBILIZATION, AND CONDITIONING REGIMEN
Because t-MDS/AML is frequently a fatal complication,
there is a need to better understand risk factors and to iden-
tify individuals at risk prior to ASCT. There are 3 contribu-
tors to risk of t-MDS/AML in this context that have been
identiﬁed: pretransplantation therapy, method of stem cell
mobilization, and transplantation conditioning regimens.
The data implicating pretransplantation therapy as a
risk factor include the demonstration that increased cumula-
tive exposure to alkylating agents increases risk, as does
prior external-beam irradiation, especially to the pelvis. In
addition, there is a relatively shorter latency of development
of t-MDS/AML in patients after transplantation compared
with t-MDS/AML in patients who have not undergone
ASCT. In addition, speciﬁc cytogenetic abnormalities have
retrospectively been identiﬁed in bone marrow cells at the
time of stem cell harvest in patients who subsequently devel-
oped t-MDS/AML [16]. Clonal hematopoiesis, as assessed
by X-inactivation–based clonality assays, has also been iden-
tified at the time of stem cell harvest in patients who
develop t-MDS/AML [17].
Several lines of evidence also indicate that the method
of stem cell collection may influence risk of developing
t-MDS/AML. For example, patients undergoing ASCT
using peripheral blood stem cells (PBSCs) have a higher risk
of developing t-MDS/AML than do those receiving bone
marrow stem cells [3,9,18]. There may be several explana-
tions for this observation, including the possibility that in the
early days of ASCT, only those patients who had inadequate
marrow harvests had PBSCs collected. This group of
patients with limited marrow reserve due to prior intensive
chemotherapy and/or radiation therapy may therefore have
been at higher risk. It has also been reported that, perhaps not
unexpectedly, patients primed with etoposide (VP-16) had a
higher risk of developing t-MDS/AML, including patients
with 11q23 and 21q22 chromosomal abnormalities [9]. It is
also clear that at least some patients who go on to develop
t-MDS/AML have no detectable cytogenetic or interphase
ﬂuorescence in situ hybridization (FISH) abnormalities at the
time of stem cell harvest, suggesting that the causal mutations
may have been induced by the conditioning regimen.
The use of TBI in the conditioning regimen appears to
be associated with an increased risk of t-MDS/AML after
ASCT [8], although a randomized trial to determine the con-
tribution of TBI to risk of t-MDS/AML has not been done.
Of note, in the one study reported from a single institution
comparing patients who did with those who did not receive
TBI, there was no increased incidence of t-MDS/AML in
those patients who received a TBI-containing regimen [9].
We have not observed an increased risk of development of
t-MDS in patients who received 1400 cGY compared to
those who received 1200 cGy. Of note, when greatly increased
doses of irradiation are delivered to the bone marrow using
high-dose radiolabeled monoclonal antibodies, t-MDS has
not emerged as a complication [19,20]. The use of prior radi-
ation therapy in our own patients appears to be associated
with a signiﬁcantly higher incidence of development of t-MDS
(P = .02). The use of prior radiation therapy has also been
previously reported as a risk factor in a series of patients
undergoing ASCT for Hodgkin’s disease [21].
Based on these observations, it is possible to minimize
risk to some extent. For example, it would seem reasonable
to not use VP-16 as a mobilizing agent for stem cell collec-
tion. Also, efforts may be undertaken to limit exposure to
pre-ASCT chemotherapy and radiation therapy, especially
in those patients who are likely, based on risk from under-
lying disease, to require ASCT as part of their therapy.
Figure 2. Criteria used to deﬁne t-MDS after ASCT at Dana-Farber
Cancer Institute.
Figure 3. Actuarial probability of development of t-MDS/AML
after ASCT.
Figure 4. Actuarial probability of survival after diagnosis of 
t-MDS/AML.
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However, it is not possible to completely eliminate the risk
associated with the conditioning regimen or pre-ASCT
chemotherapy and/or radiation therapy. In part for this rea-
son, signiﬁcant effort has been devoted to understanding the
molecular pathophysiology of t-MDS/AML in the hope that
strategies might be identiﬁed to prevent this dreaded com-
plication, or at least to identify individuals at high risk.
T-AML IS A CLONAL DISORDER
There is abundant evidence that t-MDS/AML are
clonal hemopathies. This evidence includes the presence of
cytogenetic abnormalities, including deletions (5q–, 7q–,
20q–), numerical abnormalities (+8, –7), and translocations
[11q23, t(3;21), t(15;17)]. In addition, clonal point muta-
tions have been identiﬁed in t-MDS/AML, including RAS,
FLT3, and AML1 mutations. Finally, population-based
analysis of clonality using X-inactivation assays in female
patients has convincingly demonstrated that t-MDS/AML is
a clonal disease. Thus, t-MDS/AML is a clonal disease that
is the consequence of an acquired somatic mutation that
confers a proliferative and/or survival advantage to hemato-
poietic progenitors.
MORE THAN 1 MUTATION IS NECESSARY TO CAUSE
AML, COMPLICATING INTERPRETATION OF RISK BASED
ON ANY 1 MUTATION OR GENE REARRANGEMENT
Because t-MDS/AML is a clonal disease with cytoge-
netic abnormalities, it is plausible that one could determine
risk through analysis of these molecular markers of disease.
However, there is one important caveat, which is that no
single mutation or gene rearrangement is sufﬁcient for the
development of t-AML. AML is like all other human can-
cers in requiring more than 1 mutation. Several lines of evi-
dence support this assertion, based on analysis of leukemias
associated with core binding factor (CBF) mutations and
gene rearrangements, acute promyelocytic leukemia associ-
ated with the promyelocytic leukemia and retinoic acid
receptor α (PML/RARα) gene rearrangement, and
leukemias with 11q23 rearrangements.
Several observations support the requirement for sec-
ond mutations in CBF leukemias, including analysis of the
heritable FPD/AML (familial platelet disorder with
propensity to develop AML) syndrome, the TEL/AML1
leukemias in syngeneic twins, and murine models of
AML1/ETO and CBFβ/MYH11 leukemias. CBF is a het-
erodimeric transcription factor comprising AML1 (also
known as RUNX1) and CBFβ subunits. It is a common
target of gene rearrangements, as a consequence of chro-
mosomal translocations, giving rise to the AML1/ETO,
CBFβMYH11, and TEL/AML1 fusions. In addition, point
mutations that cause loss of function of AML1 have been
identiﬁed in both inherited and sporadic leukemias.
FPD/AML syndrome is an autosomal dominant trait
characterized by a qualitative and quantitative platelet defect,
progressive pancytopenia and dysplasia with age, and pro-
gression to AML associated with acquisition of secondary
mutations. FPD/AML is caused by loss-of-function muta-
tions in the AML1 gene [22]. Thus, mutations in the AML1
component of CBF are not sufﬁcient to cause leukemia; sec-
ond mutations are required during the lifetime of affected
individuals to cause leukemia. Ford et al. have analyzed
TEL/AML1 leukemias in syngeneic twins [23]. Using
sophisticated molecular techniques, it has been possible to
demonstrate that in some syngeneic twins, each of the twins
harbors the same clone of cells containing the TEL/AML1
gene rearrangement at the time of birth, presumably because
of intrauterine transmission of a TEL/AML1-positive clone.
However, despite the syngeneic host background and car-
riage of identical TEL/AML1 clones, the twins developed
TEL/AML1-positive acute lymphoblastic leukemia (ALL) at
widely disparate times in life (at ages 5 and 14, respectively).
These data strongly indicate the need for additional muta-
tions to cause leukemia. Murine models of leukemia mediated
by AML1/ETO and CBFβ/MYH11 also provide convincing
evidence for the “2 hit” pathogenesis of disease. Expression
of either of these fusion proteins alone in hematopoietic cells
is not sufﬁcient to cause leukemia. Chemical mutagens such
as ethyl-nitrosourea (ENU) must be added to generate a
leukemia phenotype, again indicative of the need for second
mutations [24].
Similar data have been generated for PML/RARα-medi-
ated leukemias in transgenic murine models. PML/RARα is
expressed in promyelocytes in the germ line of transgenic
animals under the control of the cathepsin G promoter.
However, despite germ-line expression, animals require 4 to
6 months to develop leukemia and have karyotypically evi-
dent second mutations [25-27]. Similarly, in MLL/AF9
knockin mice, there is a long latency required for develop-
ment of leukemia [28], and MLL/CBP (mixed-lineage
leukemia and CREB binding protein) leukemias in a murine
bone marrow transplantation model require long latencies,
indicative of the need for second mutations [29].
Furthermore, leukemogenic fusions have been detected
using sensitive polymerase chain reaction (PCR)-based assays
in healthy individuals. Examples include IgH/BCL2,
BCR/ABL, MLL tandem duplication, and the TEL/AML1
fusion [30-37]. The frequency of these rearrangements is
much higher in the general population than is the risk of
developing the respective leukemias. These data indicate that
carriage of even a known leukemogenic fusion gene does not
provide useful information about the likelihood of progres-
sion to leukemia. Indeed, there are currently no data demon-
strating that PCR-detectable fusions are a risk factor for the
eventual development of leukemia. Collectively, these data
indicate that the identification of a single gene rearrange-
ment or point mutation may not necessarily be predictive of
the development of t-AML in the post-ASCT setting.
Figure 5. Methods for assessing risk of t-MDS/AML before and after
ASCT.
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METHODS FOR ASSESSING RISK OF THERAPY-RELATED
LEUKEMIA BEFORE AND AFTER ASCT
There are at least 5 methods, all of which are subject to
the caveats discussed above, for assessing risk based on the
presence of clonal abnormalities in hematopoietic cells.
These methods include standard cytogenetics, interphase
FISH, analysis for loss of heterozygosity (LOH), PCR for
point mutations, and X-inactivation–based clonality assays
(Figure 5). Each of these approaches has strengths and
weaknesses in this context.
Standard Cytogenetics 
Standard cytogenetics analyzes a limited number of
cells, typically 20 to 30, that must be capable of mitosis.
Therefore, this approach may lack sensitivity. Patients who
develop t-MDS/AML after ASCT may have normal cytoge-
netics at the time of stem cell harvest [9,16]. For example, in
22 of 612 patients with t-MDS/AML post-ASCT, none had
karyotypic abnormalities detected by standard cytogenetics.
In addition, standard cytogenetics may lack specificity. It
has been well documented that some patients who have
characteristic cytogenetic abnormalities may not develop
t-MDS/AML [4,14,38,39].
Interphase FISH 
Interphase FISH circumvents some of the frailties of con-
ventional cytogenetics (Figure 6). For example, abnormal
clones (5q–, –7, +8, –11) were detectable in pre-ASCT speci-
mens from 9 of 12 patients who developed t-MDS/AML. In
the other 3 of 12 patients, these abnormalities were below the
threshold of detection by interphase FISH [16]. An advantage
of interphase FISH is that hundreds of nonmitotic cells can be
analyzed. However, the technique is locus speciﬁc and requires
prior selection of markers for analysis, such as 5q–, 7q–, and +8.
In addition, interphase FISH is not sensitive below the level of
approximately 5% to 10% of cells. However, the identiﬁcation
Figure 6. Applications of interphase FISH to detect trisomy, monosomy, and chromosomal deletions.
Figure 7. Schematic representation of LOH in MDS. In the presence of 2 alleles, 2 bands will be apparent after PCR ampliﬁcation; whereas, if
there is allelic deletion, a single band will be seen.
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of clonal abnormalities in a high percentage of cells may indi-
cate a proliferative advantage for these cells and may be more
predictive of the development of t-MDS/AML. The speci-
ﬁcity of interphase FISH is also unknown, because we do not
know how many patients who do not develop t-MDS/AML
have interphase FISH abnormalities at the time of stem cell
harvest. The test has only been validated in retrospective stud-
ies, and it is time- and labor-intensive as a screening test.
LOH Analysis 
LOH analysis is based on loss of 1 allele at a particular
locus, usually detected by PCR analysis. This strategy can
be used to identify LOH, and to deﬁne the occurrence of
large deletions (Figures 7 and 8). LOH analysis is a
population-based assay and requires prior selection of loci
to be analyzed. It lacks sensitivity and can probably not
detect less than 20% of cells with LOH at a given locus.
However, LOH analysis is more likely to be speciﬁc, in that
a positive test indicates clonal expansion of cells with LOH.
LOH analysis is amenable to high-throughput robotic
strategies but has not yet been validated as a predictor of
post-ASCT t-MDS/AML
Figure 8. Schematic representation of the use of LOH to map deletions.
Figure 9. Human androgen receptor assay (HUMARA). A, Schema of the assay, which utilizes the variable-length CAG-repeat pattern to distin-
guish maternal from paternal X chromosome. B, Two bands will be seen after PCR ampliﬁcation in polyclonal cells where there is random inactiva-
tion. C, A single band will be seen in a clonal population. D, Results from patients studied showing polyclonal, oligoclonal, and clonal populations.
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PCR for Point Mutations and Chromosomal
Translocations
PCR for point mutations and chromosomal translocations
is emerging as a potentially useful predictor of t-MDS/AML,
as we learn more about the molecular genetics of the disease.
Markers that may be useful include mutations in RAS, FLT3,
AML1, and MLL. In addition, PCR can be used to identify
fusion transcripts including AML1/EVI1, PML/RARα, and
11q23 gene rearrangements. The PCR approach is also by
deﬁnition locus speciﬁc, and there are relatively few markers
known to date. It is highly sensitive, capable of detecting only
a few cells. But, as noted above, because some healthy indi-
viduals harbor PCR-detectable rearrangements, the speci-
ﬁcity of the assay remains to be determined in this context.
The test is probably most informative when performed using
quantitative techniques, such as the ABI770 “Taqman” PCR,
and is amenable to high-throughput analysis but has not yet
been validated as a predictor of t-MDS/AML.
X-Inactivation–Based Clonality Assay 
X-inactivation–based clonality assay requires no locus-
specific information, or indeed any information about the
nature of the mutation that causes t-MDS/AML (Figure 9).
This assay detects only clonal populations of cells that have
a proliferative advantage over normal polyclonal cells. It is
PCR based, uses DNA, and is readily amenable to high-
throughput analysis, but it is only applicable to female
patients. There are several potential pitfalls of this assay,
including false-positive test results due to germ line or
acquired skewing of the pattern of X-inactivation. However,
this problem can be circumvented in part through the
appropriate use of embryologically related tissue controls,
but the test results may be difﬁcult to interpret in cases with
severe skewing of X-inactivation patterns. This test has been
validated, however, in retrospective studies [17].
APPROACHES TO MINIMIZING RISK OF T-MDS/AML
POST-ASCT
Decreasing the risk of t-MDS/AML post-ASCT may be
approached in several ways. First, it may be appropriate to
minimize, to the extent possible, pretransplantation alkylat-
ing agents, external beam irradiation, and topoisomerase
inhibitors. This approach can be accomplished in part by
identification of high-risk individuals who are likely to
require ASCT as part of their therapy. Recent innovations in
application of both standard prognostic indicators as well as
global expression arrays may facilitate this strategy. It seems
prudent to avoid TBI as part of the conditioning regimen,
although it may be best to directly determine the risk/beneﬁt
of using TBI in a randomized trial. Alkylators and topoisom-
erase inhibitors are probably best avoided as stem cell mobi-
lizing agents, and, ﬁnally, efforts to assess risk using molecular
markers should be further explored and validated. If standard
cytogenetic results are abnormal, allogeneic transplantation
strategies, including nonmyeloablative transplantations, may
be prudent. Selected FISH loci, such as 5q–, 7q–, +8, 20q–,
and –11, should be explored prospectively as predictors of
outcome, as should X-inactivation–based clonality assays.
Effort should be devoted in pilot retrospective studies to
evaluate the role and validity of genome-wide LOH screens,
quantitative PCR for speciﬁc mutations and gene rearrange-
ments, and assessment of global expression patterns to iden-
tify signatures predictive of t-MDS/AML.
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